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Heat labile opsoning (HLO)  t to pneamococd require participation of multiple 
components of the hemolytic complement (C)  system (1). Among the compo- 
nents  required  are those inactivated by  a  purified cobra venom factor  (VF) 
(1),  which is capable of  destroying C3-C9,  without  a~ecting  C1,  C4,  or  C2 
(2). The present paper deals with the requirements for C3 and C5. 
Materials and Methods 
Phagocytic tests were performed  as described in the preceding  report (1). For reasons of 
technical convenience, all tests were done in the d//ute phagocytic system (1). Guinea pigs were 
Haztley strain males purchased from Bar F Rabbitry, Baltimore, Md. 15 ml of starch aleuronat 
suspension was injected intraperitoneally  into the guinea pigs to generate an acute granulocytic 
exudate (1). 
Three strains of pneumococcus were used: (a) an unencapsniated rough strain (PnR) (1), 
(b) a fully encapsulated type 25 strain (Pn25)  (1) of relatively high intraperitoneal virulence 
for mice (LD~o ~  10), and (c) an "intermediate" type 3  (HI SIR6) strain (Pn3-int)  with a 
relatively small capsule (3) and only a moderate intraperitoneal virulence for mice (LDio -- 
io% (4). 
Studies dealing with C5  were  done with two coisogenic  strains of inbred  black  mice: 
B10.D2/Sn "old line", deficient in C5 (CS-deficient); and B10.D2/Su "new line" not deficient 
in C5  (C5-normal)  (5-7). Both strains were purchased from the Jackson Laboratory, Bar 
Harbor, Maine. These mice possess a high degree of histocompatibility (8) and, as far as is 
known, differ only in their production of C5. 
Individual complement  components  were assayed by the method of Nelson et al. (9). 
Monospecific anti-C3 serum was prepared by immunizing rabbits with purified guinea pig 
C3 (10). 
Goat anti-rabbit globulin labeled with fluorescein isothiocyanate  was purchased from Difco 
Laboratories,  Inc.,  Detroit,  Mich. 
* These studies received support from the following sources, in addition to those listed in 
the preceding  paper (1): National Science Foundation (Grant GB-2597), the United States 
Public Health Service (Grants AI-025066 and 5 TI-AI-282-03),  and the OIfice of Naval Re- 
search (Contract 248-60). 
z Abbreviations used in this paper: EDTA,  ethylenediaminetetraacetate; HBG, modified 
Hanks' solution (1); HLO, heat labile opsonins; Pn3-int, an "intermediate" type 3 CIII SIR6) 
strain of pneumococcus; Pn25, a fully encapsulated type 25 strain of pneumocoecus; PnR, an 
unencapsulated rough strain of pneumococcus; VF, purified cobra venom factor. 
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Purified guinea pig C3 was radiolabeled with 1~I  according to the method of Greenwood 
et al. (11). The weight ratio of chloramine T  to C3 was 1:200. Measurements of radioactivity 
were  done  with  a  well  scintillation counter  containing  a  thallium-activated  NaI  crystal 
(Tracerlab, Waltham, Mass.). 
The methods used to purify C5 and the cobra venom factor are described elsewhere (12).~ 
RESULTS 
Consumption of Complement Components during Opsonization Process.--When 
either  encapsulated  (Pn25)  or  unencapsulated  pneumocci  (PnR)  (1)  were 
opsonized  by incubation in normal guinea pig serum,  they consumed a larger 
proportion of the C3 than any of the other 8 complement components (Fig.  1). 
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FIO. I.  Per cent of complement components in pooled normal guinea pig serum consumed 
by interaction with encapsulated (Pn25) and unencapsulated (PBR) pneumococci in opsoniza- 
tion reaction. The organisms were harvested in the log phase, washed twice, and resuspended 
in Hanks' bovine albumin-glucose solution (HBG)  (1)  at a  concentration of 1.25  X  101° per 
ml. 0.05 ml of the suspension was added to 1 ml of the serum and incubated for 30  rain at 
37°C. After removal of the organisms by eentrifugation the serum was titrated for the residual 
complement components (9). Their titers are expressed as percentages of the respective com- 
ponents contained in normal serum that had been similarly incubated with 0.05 ml of HBG. 
Since  C3 is the most plentiful of the C components in guinea pig serum, s it is 
clear that the principal component consumed in the reaction was C3. 
Fixation of C3 to the Organlsms.--The results of each of the following experi- 
ments indicated that C3 is fixed to the encapsulated organisms  during opsoni- 
gation. 
Type 25 pneumococci (Pn25), opsonized by being incubated twice in undi- 
luted normal guinea pig serum for 30 rain at 37°C, were washed in HBG (modi- 
fied  Hanks'  solution)  (1)  and  reincubated  in  monospecific  anti-C3  serum 
2 Cook, C. T., H. S. Shin, M. M. Mayer, and K. A. Landenslayer. The fifth component of 
the guinea pig complement system. I. Purification and characterization. To be published. 
a Shin, H. S.  Unpublished observations. H. S. SHIN, M. R. SMITH, AND  W. B. WOOD,  JR.  123I 
obtained from rabbits immunized with purified guinea pig C3 (10). The organ- 
isms so treated promptly agglutinated,  showing that  they carried  C3  on,  or 
near, their surfaces. 
The same treatment caused a capsular swelling reaction, which was difficult 
to distinguish  from the  classical  quellung  reaction  produced  by homologous 
anticapsular  antibody (Fig.  5).  The capsular swelling caused by the  anti-C3 
antibody  was  readily  blocked  by  ethylenediaminetetraacetate  (EDTA)  (1) 
and clearly indicated the presence of C3 in the capsules. 
Similarly,  the  capsules  of  Pn25,  pretreated  first  with  normal  guinea  pig 
TABLE I 
Ability of Purified C3 to Restore  Opsonie Activity of Normal Guinea Pig Serum (NGS) Pretreated 
~ith a Purified Factor of Cobra Venom (VF) 
Suspending  medium  Phag,~ytosis 
% 
NGS  82 
VF-treated NGS  0 
W-treated NGS +  C3  85 
C3 in HBG  0 
HBG  0 
To inactivate C3 without appreciably affecting C5 (see Table II), 0.86 #g of VF (12) was 
added to 1 ml of NGS and incubated at 37°C for 15 rain. To restore C3 activity, 1.2 mg of 
purified C3 in 0.2 ml of Hanks' bovine albumin-glucose  solution (HBG) (1) was added to the 
1 ml of VF-treated serum. When the C3 was tested alone as an opsonin, the same amount was 
dissolved in 1 ml of HBG. The phagocytic tests were done with encapsulated pneumococci 
(Pn25) and with guinea pig exudate leukocytes. Although the quantity of VF required to in- 
activate most of the C3, without inactivating C5 (Table II), varied somewhat with different 
lots of NGS and VF, the results recorded in this table were highly reproducible in repeated 
experiments. 
serum and then with  the monospecific anti-C3  rabbit serum,  stained  specifi- 
cally with fluorescein-Iabeled goat antiserum to rabbit globulin (Fig.  6).  This 
finding further substantiated the presence of C3 in the capsules of the serum- 
treated organisms. 
Finally,  to demonstrate more directly the  capsular uptake of C3,  6.25  X 
108 Pn25 were twice incubated at 37°C for 30 rain in 1 ml of normal guinea pig 
serum containing 10 #g of purified x26I-labeled  C3 (1I). After being washed in 
HBG,  the organisms retained  5.3%  of the  total radioactivity of the serum; 
whereas the uptake from heated serum  4 was 1.3 %  and from serum containing 
0.01 x~ EDTA (1) was only 0.9%. 
Role of C3 in Opsonization.--Addition  of less than 1 #g of a purified fraction 
4  Labeled C3 was added after serum had been heated at 56°C for 30 min. 1232  HEAT LABILE OPSONINS TO PNEUMOCOCCUS. II 
of cobra venom (VF)  (12)  to 1 rnl of guinea pig serum destroyed more than 
95 %  of the C3 activity of the serum without causing a detectable loss of C1, 
C4, or C2 (2,  12) and without significantly depressing the activity of C5 (see 
Table  II).  The  opsonic  activity,  which  was  completely suppressed  by  the 
treatment, was fully restored by the addition of 1.2 mg of purified C3 (Table 
I, lines  1-3).  This finding indicates that  C3 is critically involved in the op- 
sonization process. The failure of C3 alone to act as an opsonin (Table I, line 
4) suggests that it must be "activated", presumably to C3b (13), before it can 
participate in the reaction. 
TABLE II 
The Effea~ of Larger Doses of Purified Cobra Venom Faaor on the Activilies of C3, C5, amt HID 
in Normal Guinea Pig Serum 
VF added to NGS  C3 inactivated  C5 inactivated  C3 added  Phagocytosis 
%  %  mg  % 
0  0  0  0  83 
0.86  95  10  0  0 
0.86  --  10  1.2  85 
2.57  95  30  0  0 
2.57  --  30  1.2  51 
7.70  95  73  0  0 
7.70  --  73  1.2  3 
Where blanks are left in the table, large excesses  of C3 were added to the serum, and hence 
per cent inactivation of normal C3 levels could not be determined. The experiments were 
performed as described in Table I. 
As the dosage of VF was raised, increasing amounts of C5 were inactivated, 
in addition to the C3 (Table II). Under these circumstances, the added C3 was 
proportionately less  effective in  restoring the  opsonic activity of the serum 
(Table II, lines 3, 5, and 7). Kinetic measurements of C3 inactivation, however, 
revealed that these higher doses of VF rapidly destroyed the C3 added to the 
serum (Fig. 2). Since the added C3 may therefore have been inactivated before 
it could participate in the opsonization process, no conclusion could be drawn 
about the possible involvement of later acting components (C5-C9). 
Requirement for  C5.--To  test for possible participation  of C5-C9,  experi- 
ments were pedormed with C5-deficient mouse serum (5-7). Its promotion of 
phagocytosis, when tested with Pn25  (Table III), was slightly less than that 
of coisogenic mouse serum, and the deficiency was at least partially reversible 
with  purified  C5.  A  similar  deficiency could be demonstrated in vitro with 
Pn3-int (Table IV). 
The participation of C5 in antipneumococcal defense could also be demon- 
strated in vivo, provided the pneumococcal strain inoculated intraperitoneally H.  S.  SHIN~  M.  R.  SMITH,  AND  W.  B.  WOOD~ JR.  1233 
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FI¢. 2. Kinetics of C3 inactivation by varying doses of purified venom factor 0/F). The 
VF was dissolved in 0.15 ~ NaCI and added to 3 volumes of serum. The four serum samples 
were treated  with 0  (O  O), 0.86 (A  ....  ~),  2.57 ([:3  O),  and 7.70 (O  O) 
#g of VF. To the treated samples at 0°C was added 0.1 part of purified C3 dissolved in 0.15 
NsCl buffered with 0.005 K phosphate st pH 7.5. The reaction mixtures were incuhated at 
37°C, and the reactions were terminated  at the times indicated in the chart by diluting the 
samples 1000-fold in ice cold glucose-gelstin verona] buffer containing 0.15 n~ Ca  ++ and 1.0 
m~ ++  (9). 
TABLE III 
Phagocytosis  of Encapsula~i  Pneamococci  (Pn25)  in  Sera  of Coisogeni¢ CS-Defic'i~t  and 
C-Normal Mice 
Suspending medium 
Phasocytosis 
Exp:  1  2  3  4  5 
% 
C-normal serum  35  36  35  51  33 
CS-deficient serum  22  26  25  34  19 
C5-deficient serum -F purified guinea pig  27  39  33  41  26 
C5 
The phagocytic tests were done with both isologous and homologous exudate leukocytes. 
The purified guinea pig C5  g used  to restore  the activity of  the C5-deficlent serum  was 
added in a concentration of 15 #g per ml in the first four experiments and 150 pg per ml in 
the fifth. 
was not too virulent (see Discussion). In a  preliminary experiment using ten- 
fold dilutions of a  16 hr culture of Pn3-int (3) and inoculating 6 mice at each 
dilution, it was found that the LVs0 for the C normal mice was about 10 times 
greater than that for the C5-deficient mice. This difference was confirmed in a 
second more complete experiment in which the intraperitoneal inocula were 
varied two-fold and the mice were infected in groups of 10 (Table V  and Figs. 1234  HEAT  LABILE  OPSONINS  TO  PNEUMOCOCCUS.  II 
TABLE IV 
~kagocytosis of Pn3-int in C-Normal and CS-Deficient Mouse Serum 
Suspending medium 
Phagocytosis 
Exp:  1  2  3 
% 
C-normal serum  31  32  24 
C5-deficient serum  21  11  8 
TABLE  V 
The Effect of C5 Deficiency on Survival of Mice Ckallenged Inlraperi~neally  wifk Varying Doses 
of Pn3gnt 
No. of  C5  Survivors on dsys:  Dead/ 
Dose  mice  2  3  4  5  6  7  8  total* 
1.3 X  l0  s  10  +  9  4  3  2  2  2  2  8/10 
10  --  4  0  0  0  0  0  0  10/I0 
6.4X  10  7  10  +  10  10  i0  7  7  7  7  3/10 
10  --  8  i  1  1  1  1  1  9/10 
3.2X107  10  +  10  10  10  5  3  3  3  7/10 
10  -  9  3  I  1  1  1  1  9/10 
1.6X10 7  10  +  10  10  8  7  7  7  7  3/10 
10  -  9  5  2  2  2  2  2  8/10 
8.0X10 e  10  +  10  10  10  10  10  10  10  0/i0 
10  -  10  7  2  1  1  0  0  10/10 
4.0X  I0  ~  10  +  10  10  10  10  10  10  10  0/10 
10  --  10  8  4  0  0  0  0  10/10 
2.0X  10  e  10  +  10  10  10  I0  10  10  10  0/10 
10  --  10  10  8  6  6  6  6  4/10 
1.0X  10  6  10  +  10  10  10  10  10  10  10  0/10 
10  --  10  10  10  10  10  10  10  0/10 
5.0X  10  5  10  +  10  10  10  10  10  10  10  0/10 
10  --  10  10  9  9  9  9  9  1/10 
* Pn3-int was cultured from the blood of every mouse that died during the experiment. 
3  and 4).  The  LDso values for the  C5-normal  and  C5-deficient  mice,  as  calcu- 
lated by the Reed-Muench  method  (14,  15), were  10  TM and  10  6"6, respectively. 
It  should be noted  that  at two of the inoculation levels (Table V,  lines 5  and 
6),  all  of  the  CS-deficient  mice  died,  whereas  all  of  the  C-normal  mice  sur- 
vived. H.  S.  SKI:hT, M.  R.  SMITH, AND W.  B.  WOOD, JR.  1235 
DISCUSSION 
It is clear from the present studies that activated C3  (i.e.,  C3b)  plays a 
major role in the opsonization of encapsulated pneumococci by normal mam- 
malian sera. 
This finding is of great theoretical interest in relation to the recent detection 
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of C3 reactive sites (or more specifically C3b reactive sites) on the surfaces of 
both granulocytes (16) and monocytes (16, 17). These sites have been shown to 
participate in the imraunoadhesion of  sensitized  erythrocytes to phagocytic 
cells  (18)  and in the erythrophagocytosis that follows.  In this system, anti- 
bodies to surface antigens of the erythrocytes fix the complement components 
to  the  surfaces  of  the  erythrocytes and  thus render  them  "sticky" to  the 
phagocytes.  The  principal  ligand between the  erythrocytes and  the  phago- 1236  HEAT  LABILE  OPSONINS  TO  PNEUMOCOCCUS.  II 
cytes appears  to be C3b, since sensitized erythrocytes carrying C1, 4, 2a, 3b 
are opsonized, whereas those carrying only C1, 4, 2a are not (19). 
The results  of the present experiments indicate that the same ligand (C3b) 
is critical  in the pneumococcus-HLO system. As already noted (1), however, 
the  antibodies  that initiate fixation  of  the  complement  components  to the 
bacterial surfaces  have not been  positively identified.  Presumably they are 
natural antibodies  to cell wall  antigens that are  shared by many bacterial 
species. In keeping  with this presumption are the following facts: (a)  such 
natural antibodies are known to exist in mammalian sera (20); (b) HLO have 
consistently been shown to be immunologically polyspecific (20); and (c) their 
action is not Mocked by an excess of homologus type specific capsular antigen 
(1). Nevertheless,  the possibility must also be considered that C3 is fixed and 
activated by an alternative pathway that does not involve  an antigen-anti- 
body reaction.  Regardless of the precise mechanism by which the C3 is fixed 
to the pneumococcus,  once enough  C3b  molecules have  accumulated in its 
capsule, opsonization results. 
The role of C5 in promoting the phagocytosis of encapsulated pneumococci 
seems to be relatively minor as compared  to that of C3. Nevertheless,  a deft- 
nite C5 effect was demonstrated both in vitro and in vivo. 
The observation  that the CS-deficient mice were more susceptible to pneu- 
mococcal peritonitis than the coisogenic C-normal  mice indicates that C5 is 
somehow involved  in the mouse's antipneumococcal  defense. Demonstration 
of this difference depended upon the selection of a pneumococcal strain (Pn3- 
int) with just the right degree of virulence. An attempt to perform the experi- 
ment with Pn25  was  unsuccessful  because  most of the  C-normal  mice  suc- 
cumbed to even the smallest intraperitoneal inoculum (LDs0 <  10). 
As has  already been  emphasized  elsewhere  (21), significant  differences in 
antibacterial resistance often go undetected when the challenge strain is either 
too virulent or too easily phagocytized.  In analogous  experiments  with the 
same two mouse strains,  Caren and Rosenberg  (22) have recently found that 
the C-normal  mice are slightly more resistant than the C5-deficient mice to 
intravenous injections  of Corynebacterium kutscheri. The delicate host-parasite 
balance in this experimental model is complicated  by the common occurrence 
of latent C. kutscheri infections in mice (23); but despite this complication, C5 
appears  to play a definite role in the host's defenses. In contrast, Stiffel et al. 
(24) and Glynn and Medhurst (25), using the same two strains of mice, were 
unable to detect any difference in their ability to clear relatively large intra- 
venous doses of radiolabeled Salmonella typhi and Escherichla coll. Such models, 
of course, do not simulate bacterial disease and, therefore, are of limited value 
in studying many phases of phagocytosis  and antibacterial immunity (21, 26, 
27). 
How CS contributes to antibacterial immunity is not known.  It may con- H.  S.  SHIN,  M.  R.  SMITH,  AND  W.  B.  WOOD, JR.  1237 
ceivably act as an accessory opsonln  after reacting with C3 on the bacterial 
cell, or the chemotactic CSa fragment that is  released during  the  reaction 
(28) may stimulate the phagocytes. Both possibilities are being investigated. 
It is evident from the present studies that components of the complement 
system, acting as HLO, participate in antipneumococcal defense, particularly 
in the preantibody phase of pneumococcal disease. When the organisms  first 
gain  a  foothold in  the  tissues,  the  resulting inflammatory response  brings 
granulocytes and plasma to the lesion. Although the granulocytes alone can 
destroy some of the invading organisms by surface phagocytosis (21, 26), the 
efl3ciency of phagocytosis is  greatly increased by the HLO  in  the plasma 
Since the action of HLO is imraunologically polyspecific, it does not require the 
presence of specific anticapsular antibodies.  When these antibodies eventually 
do arrive in the lesion, however, phagocytosis becomes still more efficient (29~ 
30). Even at this stage complement is evidently involved, for its presence has 
long been known to  accelerate the phagocytosis of pneumococci opsonized 
with anticapsular antibody (31). Very recently, the complement components 
required for this acceleration have been shown to be the same as those that 
promote the phagocytosis of sensitized erythrocytes, namely CI, C4, C2, and 
C3 (32). 
The synergistic action of IgG and C3b molecules as opsonins must now be 
considered in relation to the corresponding  reactive sites  that have recently 
been demonstrated on the surfaces of phagocytes (16, 17). In early pneumococ- 
cal disease, before enough anticapsular antibody has been generated to neu- 
tralize the capsular antigen in the fluid phase of the lesion (30), the C3b reac- 
tive sites are apparently involved in the HI.O-promoted phagocytosis.  Once 
enough anticapsular IgG has accumulated, on the other hand,  both sets of 
reactive sites may participate in the phagocytic process. The IgG reactive sites 
are presumably to the Fc portion of the specific IgG molecules that are acting 
as opsonins (33). Determination of the relative degrees to which the two kinds 
of reactive sites participate in the ingestion of pneumococci, when both anti- 
capsular IgG and complement are present in the system, will require further 
quantitative studies in vitro. 
SDMMAR~ 
When encapsulated type 2S pneumococci (Pn2S) were opsonized with normal 
guinea pig serum, they consumed much more C3 than other complement (C) 
components. Fixation of C3  to  the organisms  was demonstrated by radio- 
labeling techniques, and its capsular localization was established by the use of 
monospecific anti-C3  antibody. 
Treatment of the serum with an appropriate dose of a purified cobra venom 
factor (VF) destroyed C3 and all of the opsonic activity, without appreciably 
affecting the other C components.  Addition of purified C3 completely restored 1238  HEAT  LABILE OPSONINS TO PNE~OCOCCUS.  II 
the opsonic activity of the VF-treated serum, indicating a requirement for C3. 
Since purified C3 alone had no opsonic activity, it was concluded that the C3 
molecules had to be cleaved (to C3b)  to function as opsonins. 
Experiments with C5-deficient mice revealed that  C5  also plays a  definite, 
but quantitatively less impressive, role in antipneumococcal defense. 
The authors wish to thank Dr. M. M. Mayer for many helpful suggestions and criticisms 
and J. Messenheimer and K. Laudenslayer for superb technical assistance. 
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FIG.  5.  Capsular  swelling  reaction  caused  by  incubating type  25  pneumococci 
(Pn25) at 37°C for 30 min, twice with normal guinea pig serum and once with mono- 
specific anti-C3 rabbit serum (10). The quellung  reaction thus induced is shown in the 
right upper panel. The organisms in the panel below (right lower) were treated in the 
same manner except that enough EDTA (0.01 ~) was added to the guinea pig serum 
to block the uptake of the heat labile opsonins (1). In the left upper panel, for compari- 
son, is shown the capsular swelling of Pn25 caused by treatment with anti-Pn25 rab- 
bit serum, and in the left lower  panel are  Pn25 treated with normal rabbit serum 
( X  20O0). 
FIG. 6.  Type 25 pneumococci pretreated with normal guinea pig serum and mono- 
specific anti-C3 rabbit serum (as in Fig. 5) and then exposed to goat anti-rabbit globu- 
lin conjugated with  fluorescein  isothiocyanate. Before  the  fluorescein-labeled anti- 
rabbit globulin was added  to the pneumococci, they were washed twice  in HBG to 
remove the residual anti-C3 rabbit serum.  (Fluorescence microscopy,  X  2000). H.  S.  SHIN,  M.  R.  SMITH,  AND  W.  B.  WOOD~ JR.  1241 